Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4Ã7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and MORF-720 and MORF-627, which is in the preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases. The company is also developing avÃ1 for the treatment of fibrotic diseases, and avÃ8 to treat solid tumors, as well as various other products. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with Schrödinger, LLC for integrin targets; and a license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. to discover or develop integrin-based therapeutics. Morphic Holding, Inc. was incorporated in 2014 and is based in Waltham, Massachusetts.
IPO Year: 2019
Exchange: NASDAQ
Website: morphictx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/8/2023 | $46.00 | Buy | Citigroup |
| 9/25/2023 | $61.00 → $33.00 | Hold | Stifel |
| 9/25/2023 | Buy → Neutral | BTIG Research | |
| 8/9/2023 | $69.00 → $61.00 | Buy → Hold | Stifel |
| 9/7/2022 | $44.00 | Buy | Stifel |
| 7/20/2022 | $45.00 | Outperform | SVB Leerink |
| 3/31/2022 | $68.00 | Buy | Canaccord Genuity |
| 2/25/2022 | $82.00 → $76.00 | Outperform | RBC Capital |
| 2/11/2022 | $64.00 | Buy | BTIG |
| 12/8/2021 | $81.00 | Overweight | Wells Fargo |